
Sign up to save your podcasts
Or


In this podcast, Dr. Valentin Fuster reviews findings from the SUMMIT trial, which examined how tirzepatide impacts patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and chronic kidney disease (CKD). The study revealed that while tirzepatide improved cardiovascular outcomes and slightly boosted kidney function, the benefits in CKD patients may stem from mechanisms beyond glomerular filtration alone.
By American College of Cardiology4.2
161161 ratings
In this podcast, Dr. Valentin Fuster reviews findings from the SUMMIT trial, which examined how tirzepatide impacts patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and chronic kidney disease (CKD). The study revealed that while tirzepatide improved cardiovascular outcomes and slightly boosted kidney function, the benefits in CKD patients may stem from mechanisms beyond glomerular filtration alone.

137 Listeners

320 Listeners

497 Listeners

885 Listeners

18 Listeners

31 Listeners

3,343 Listeners

140 Listeners

1,156 Listeners

61 Listeners

41 Listeners

195 Listeners

364 Listeners

430 Listeners

371 Listeners